Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
Healthcare
$21.04 -0.96%
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
52W Low $14.39High $36.03
Volume 0.17M
Average 0.20M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$60.08M
FY 2025 · Annual
Investing Cash Flow
-$138,000.00
FY 2025 · Annual
Financing Cash Flow
$173.35M
FY 2025 · Annual
+1.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.93M) | (32.18K) | (42.82M) | (57.98M) | (74.15M) |
| Depreciation & Amortization | 364K | 1.01K | 1.48M | 1.65M | 1.38M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 639K | 1.12K | 1.12M | 3.49M | 10.5M |
| Change in Working Capital | 1.92M | (7.4M) | (584K) | (10.28M) | (70K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.45M | (3.1M) | (165K) | (1.42M) | 116K |
| Other Working Capital | 464K | (4.3M) | (419K) | (8.86M) | (186K) |
| Other Non-Cash Items | (6.45M) | (89.78M) | 127K | 4.04M | 2.27M |
| Operating Cash Flow | (12.45M) | (97.21M) | (40.68M) | (59.08M) | (60.08M) |
| Capital Expenditures | (2.12M) | (267K) | (279K) | (156K) | (208K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.12M) | (267K) | (279K) | (156K) | (138K) |
| Debt Repayment | 3.61M | (393K) | (499K) | (475K) | (489K) |
| Common Stock Issued | 2K | 262K | 34.13M | 94.6M | 174.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 393K | 121K | 77.59M | (485K) |
| Financing Cash Flow | 41.42M | 262K | 33.75M | 171.71M | 173.36M |
| Effect of Forex Changes | 0 | 492K | 16K | (8K) | (95K) |
| Net Change in Cash | 26.84M | (96.72M) | (7.2M) | 112.47M | 113.04M |
| Free Cash Flow | (14.58M) | (97.48M) | (40.96M) | (59.24M) | (60.29M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$74.2M
+ D&A$1.4M
+ Stock-Based Comp$10.5M
+ Deferred Tax$0
- Working Capital-$70.0K
+ Other Non-Cash$2.3M
= Operating Cash Flow-$60.1M
- Capex-$208.0K
= Free Cash Flow-$60.3M
Analysis
FY2025 free cash flow is -$60.3M. FCF conversion is 81.3% of net income. Operating cash flow was -$60.1M, with capex of -$208.0K. The largest bridge item is Stock-Based Comp at $10.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
Does TECX generate free cash flow?
Tectonic Therapeutic, Inc. (TECX) generated -$60.29M of free cash flow in fiscal 2025.
How much operating cash flow does TECX produce?
Operating cash flow was -$60.08M, before capital expenditures of $208,000.00.
Continue the stock analysis
Jump to another research area for this company.